Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Express Scripts
Medtronic
AstraZeneca
Baxter
Harvard Business School
Johnson and Johnson

Last Updated: December 14, 2019

DrugPatentWatch Database Preview

Details for Patent: 6,676,929

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Which drugs does patent 6,676,929 protect, and when does it expire?

Patent 6,676,929 protects ABLAVAR and is included in one NDA.

This patent has forty-three patent family members in twenty-six countries.

Summary for Patent: 6,676,929
Title: Diagnostic imaging contrast agents with extended blood retention
Abstract:The present invention relates to contrast agents for diagnostic imaging with prolonged blood retention. In particular, this invention relates to novel compounds that are characterized by an image enhancing moiety (IEM); a protein plasma binding moiety (PPBM); and a blood half-life extending moiety (BHEM). This invention also relates to pharmaceutical compositions comprising these compounds and to methods of using the compounds and compositions for blood half-life extension and contrast enhancement of diagnostic imaging.
Inventor(s): McMurry; Thomas J. (Winchester, MA), Sijiki; Hironao (Gifu, JP), Scott; Daniel M. (Acton, MA), Lauffer; Randall B. (Brookline, MA)
Assignee: Epix Medical, Inc. (Cambridge, MA)
Application Number:10/034,522
Patent Claim Types:
see list of patent claims
Compound; Composition;

Drugs Protected by US Patent 6,676,929

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Lantheus Medcl ABLAVAR gadofosveset trisodium SOLUTION;INTRAVENOUS 021711-001 Dec 22, 2008 DISCN No No   Start Trial   Start Trial Y   Start Trial
Lantheus Medcl ABLAVAR gadofosveset trisodium SOLUTION;INTRAVENOUS 021711-002 Dec 22, 2008 DISCN No No   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Johnson and Johnson
Harvard Business School
Merck
Express Scripts
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.